Real-Life Safety of Doravirine in Treatment-Experienced, Virologically Suppressed PLWHIV

Affiliations

¹ Infectious Diseases Unit, San Salvatore Hospital, L'Aquila, Italy.
² Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy.
³ Infectious Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Comment

Arturo Ciccullo et al. J Acquir Immune Defic Syndr. 2021.

. 2021 Sep 1;88(1):e5-e6.

doi: 10.1097/QAI.0000000000002730.

¹ Infectious Diseases Unit, San Salvatore Hospital, L'Aquila, Italy.
² Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy.
³ Infectious Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

No abstract available

Comment on

Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.
Kumar P, Johnson M, Molina JM, Rizzardini G, Cahn P, Bickel M, Wan H, Xu ZJ, Morais C, Sklar P, Greaves W; DRIVE-SHIFT Study Group. Kumar P, et al. J Acquir Immune Defic Syndr. 2021 Jun 1;87(2):801-805. doi: 10.1097/QAI.0000000000002642. J Acquir Immune Defic Syndr. 2021. PMID: 33633036 Free PMC article. Clinical Trial.

1. Kumar P, Johnson M, Molina JM, et al. Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through week 144 in the DRIVE-SHIFT trial. J Acquir Immune Defic Syndr. 2021;87:801-805.
1. Talwani R, Temesgen Z. Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection. Drugs Today (Barc). 2020;56:113–124.
1. Feng M, Sachs NA, Xu M, et al. Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations. Antimicrob Agents Chemother. 2016;60:2241–2247.
1. Fulco PP, Herity LB. Doravirine use in treatment-experienced HIV-positive patients. Ann Pharmacother. 2021;55:127–130.
1. Ankrom W, Yee KL, Sanchez RI, et al. Severe renal impairment has minimal impact on doravirine pharmacokinetics. Antimicrob Agents Chemother. 2018;62:e00326-18.